ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.44
-0.52%
US Tech 100
21,191.20
0.62%
S&P 500
6,051.09
0.00%
US Dollar vs CAD
1.42365
0.00%
Bitcoin
104,541.80
3.09%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Basilea Pharmaceutica Ag (0QNA)

  7. Basilea Pharmaceutica Ag (0QNA) News

0QNA

Basilea Pharmaceutica (0QNA)

Basilea Pharmaceutica Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QNA
DateTimeSourceHeadlineSymbolCompany
10/10/202412:15AMUK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearLSE:0QNABasilea Pharmaceutica Ag
10/10/202412:15AMUK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
09/24/202412:15AMUK RegulatoryBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisLSE:0QNABasilea Pharmaceutica Ag
09/24/202412:15AMUK RegulatoryBasilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver CandidiasisLSE:0QNABasilea Pharmaceutica Ag
09/19/202412:15AMUK RegulatoryBasilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial fundingLSE:0QNABasilea Pharmaceutica Ag
09/19/202412:15AMUK RegulatoryBasilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste FörderungLSE:0QNABasilea Pharmaceutica Ag
09/06/202412:15AMUK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
09/06/202412:15AMUK RegulatoryStarke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
08/27/202412:15AMUK RegulatoryEntscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
08/27/202412:15AMUK RegulatoryEuropean Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
08/21/202412:15AMUK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
08/21/202412:15AMUK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
08/13/202412:15AMUK RegulatoryBasilea meldet starke Halbjahresergebnisse 2024 und erhöht signifikant den Ausblick für Umsatz und Gewinn für das GesamtjahrLSE:0QNABasilea Pharmaceutica Ag
08/13/202412:15AMUK RegulatoryBasilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidanceLSE:0QNABasilea Pharmaceutica Ag
06/20/202412:15AMUK RegulatoryBasilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
06/20/202412:15AMUK RegulatoryBasilea partners oncology drug candidate lisavanbulin with Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
05/16/202412:15AMUK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
05/16/202412:15AMUK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
05/03/202412:15AMUK RegulatoryBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
05/03/202412:15AMUK RegulatoryBasilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
04/24/202411:00AMUK RegulatoryBasilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des VerwaltungsratsLSE:0QNABasilea Pharmaceutica Ag
04/24/202411:00AMUK RegulatoryBasilea shareholders approve all proposals of the board of directors at the annual general meetingLSE:0QNABasilea Pharmaceutica Ag
04/09/202412:15AMUK RegulatoryBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsLSE:0QNABasilea Pharmaceutica Ag
04/09/202412:15AMUK RegulatoryBasilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-WirkstoffklasseLSE:0QNABasilea Pharmaceutica Ag
04/04/202412:15AMUK RegulatoryBasilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekanntLSE:0QNABasilea Pharmaceutica Ag
04/04/202412:15AMUK RegulatoryBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsLSE:0QNABasilea Pharmaceutica Ag
03/11/20241:15AMUK RegulatoryContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
03/11/20241:15AMUK RegulatoryAnhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
02/13/202412:15AMUK RegulatoryBasilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-PortfolioLSE:0QNABasilea Pharmaceutica Ag
02/13/202412:15AMUK RegulatoryBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioLSE:0QNABasilea Pharmaceutica Ag
 Showing the most relevant articles for your search:LSE:0QNA

Your Recent History

BIT
P1SH78
BNP Paribas Issuance
BIT
I08367
Intesa Sanpaolo
BIT
UC3XAJ
Unicredit Bank
BIT
I09311
Intesa Sanpaolo
BIT
P1RLO3
BNP Paribas Issuance
BIT
SJPM5L
Societe Generale Effekten
BIT
I08364
Intesa Sanpaolo
BIT
UC9154
Unicredit Bank
BIT
UC84FW
Unicredit Bank
ASX
AMO
Ambertech
BIT
UIG168
Unicredit Bank
BIT
UC4YAJ
Unicredit Bank
BIT
UB8R4N
Unicredit Bank
BIT
I10536
IT0005616815 20250602 34.5
BIT
UC8K3G
Unicredit Bank
BIT
UIJ413
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved